Skip to main content

MEDICINA PERSONALIZADA PARA LA OPTIMIZACION DEL TRATAMIENTO INMUNOMODULADOR EN PACIENTES CON UVEITIS (MEDPOTIV).

PI20/00719

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model

  • Bermúdez, María José
  • García-Otero, Xurxo
  • Mondelo-García, Cristina
  • González, Francisco
  • Pérez-Fernández, Román
  • Avila, Leandro
  • Antúnez, José
  • González-Barcia, Miguel
  • Adán, Alfredo
  • Aguiar, Pablo
  • Otero Espinar, Francisco Javier
  • Fernández Ferreiro, Anxo
[Abstract] Background: Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has already demonstrated safety and effectiveness in other ocular pathologies. However, TAC eye drops are not marketed, thus their elaboration must be carried out in Hospital Pharmacy Departments (HPDs). Methods: 32 Sprague-Dawley rats were divided into 4 groups of 8 rats each: (a) untreated healthy rats (Healthy); (b) untreated Endotoxin-Induced Uveitis model-rats (EIU); (c) EIU-rats treated with standard treatment of dexamethasone ophthalmic drops (DXM) and (d) EIU-rats treated with TAC-hydroxypropyl-β-cyclodextrin eye drops previously developed by our group (TAC-HPβCD). The mRNA expression levels of IL-6, IL-8, MIP-1α and TNF-α, quantitative analysis of leucocytes in aqueous humor and histological evaluation were performed. Results: TAC-HPβCD eye drops demonstrated to reduce ocular inflammation, expression of IL-6, TNF-α, MIP-1α and leukocyte infiltration in aqueous humor. Conclusions: TAC-HPβCD eye drops showed beneficial effect in EIU model in rats, positioning as an alternative for uveitis treatment in case of corticosteroids resistance or intolerance., This project was partially funded by Health Research Institute Carlos III (PI20/00719, RETICS RD16/0008/0003), FEDER, Axencia Galega Innovación (Grupos de Potencial Crecimiento IN607B2020/11 y Grupo de Referencia Competitiva ED431C2021/01) and Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100). X. García-Otero is grateful to the IDIS (Health Research Institute of Santiago de Compostela) for financing his predoctoral research fellowship. C. Mondelo-García and A. Fernández-Ferreiro are grateful to the Carlos III Health Institute for financing their personnel contracts: JR20/00026 and JR18/00014., Xunta de Galicia; IN607B2020/11, Xunta de Galicia; ED431C2021/01
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Microbiome in Immune-Mediated Uveitis

  • Poza, Margarita
  • Rodríguez-Fernández, Carmen Antía
  • Busto Iglesias, Manuel
  • Domingo, Begoña de
  • Conde-Pérez, Kelly
  • Vallejo, J. A.
  • Rodríguez Martínez, Lorena
  • González Barcia, Miguel
  • Llorenç, Victor
  • Mondelo-García, Cristina
  • Fernández Ferreiro, Anxo
[Abstract] In the last decades, personalized medicine has been increasing its presence in different fields of medicine, including ophthalmology. A new factor that can help us direct medicine towards the challenge of personalized treatments is the microbiome. The gut microbiome plays an important role in controlling immune response, and dysbiosis has been associated with immune-mediated diseases such as non-infectious uveitis (NIU). In this review, we gather the published evidence, both in the pre-clinical and clinical studies, that support the possible role of intestinal dysbiosis in the pathogenesis of NIU, as well as the modulation of the gut microbiota as a new possible therapeutic target. We describe the different mechanisms that have been proposed to involve dysbiosis in the causality of NIU, as well as the potential pharmacological tools that could be used to modify the microbiome (dietary supplementation, antibiotics, fecal microbiota transplantation, immunomodulators, or biologic drugs) and, consequently, in the control of the NIU. Furthermore, there is increasing scientific evidence suggesting that the treatment with anti-TNF not only restores the composition of the gut microbiota but also that the study of the composition of the gut microbiome will help predict the response of each patient to anti-TNF treatment., Funding This work was partially supported by ISCIII co-funded by FEDER (PI20/00719, PI20/00413) and by Xunta de Galicia IN607D 2021 and IN607A 2020/05. Acknowledgments CMG and AFF acknowledge the support of Instituto de Salud Carlos III (ISCIII) by research grants (JR20/0026 and JR18/00014)., Xunta de Galicia; IN607D 2021, Xunta de Galicia; IN607A 2020/05